The company has enrolled the first patient in the second human trial of its implantable metabolite monitoring system, which it expects could change the game for blood glucose measurement.
Indigo Diabetes has enrolled the first patient in its SHINE study to test the accuracy of its subcutaneously implanted continuous multi-metabolite (CMM) measuring device.
SHINE will enroll up to 15 participants with diabetes who will attend trial sites for a total of eight measurement...
Create an account to read this article
Already a subscriber?
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”
Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
